<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409369</url>
  </required_header>
  <id_info>
    <org_study_id>BP25485</org_study_id>
    <secondary_id>2011-000916-24</secondary_id>
    <nct_id>NCT01409369</nct_id>
  </id_info>
  <brief_title>A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819</brief_title>
  <official_title>A Single-Center, Open-Label, Two-Period Crossover Study to Investigate the Effect of Multiple Doses of Activated Charcoal on the Pharmacokinetics of a Single Oral Dose of RO4995819 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, two period crossover study will evaluate the effect of multiple doses of&#xD;
      activated charcoal on the pharmacokinetics of a single oral dose of RO4995819 in healthy&#xD;
      volunteers. Each enrolled subject will receive two single oral doses of RO4995819 separated&#xD;
      by a wash-out period of up to 9 weeks. In period 1, subjects will receive concomitantly with&#xD;
      the single dose of RO4995819 multiple oral doses of activated charcoal until Day 7. In period&#xD;
      2, only a single dose of RO4995819 but no activated charcoal will be administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C max: maximum observed plasma concentration</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T max: time of maximum observed plasma concentration</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2: apparent terminal half-life</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC: area under the plasma concentration-time curve</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4995819</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activated charcoal</intervention_name>
    <description>orally 3 times daily, Days 1-7</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects, 18 to 65 years of age, inclusive&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 30 kg/m2 inclusive&#xD;
&#xD;
          -  All subjects must agree to use a barrier method (e.g. condom) throughout the study and&#xD;
             for up to 5 months after the last dose of study drug&#xD;
&#xD;
          -  Significant past or present disorders of the central nervous system, psychiatric&#xD;
             disorders or behavioral disturbances.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C, or HIV 1 or HIV 2&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 3 months prior to&#xD;
             first administration of the study drug&#xD;
&#xD;
          -  Any confirmed allergic reaction against any drug or multiple allergies&#xD;
&#xD;
          -  Dietary restrictions that would prohibit the consumption of standardized meals&#xD;
&#xD;
          -  Positive cotinine test and/or any use of nicotine containing products&#xD;
&#xD;
          -  Clinically relevant history of constipation or bowel disorder&#xD;
&#xD;
          -  Known intolerability to activated charcoal&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

